# US 2017/0254807 A1 · Method For Detecting And Purifying Pancreatic Beta Cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0254807 A1
- Document ID: US20170254807A1
- Status: Published application
- Kind: A1
- Application number: 15/457,973
- Filed: 2017-03-13
- Published: 2017-09-07
- Earliest claimed: 2008-11-07
- Assignees: The Cleveland Clinic Foundation; The Regent of the University of Colorado, A Body Corporate
- Applicants: The Cleveland Clinic Foundation; The Regent of the University of Colorado, A Body Corporate
- Inventors: Jan Jensen; John Hutton; Xiaoling Qu; Howard Davidson
- Web page: https://patentgrep.com/patent/US20170254807A1

## CPC

- G01N 33/56966: {Animal cells}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 5/0676: {Pancreatic cells}
- G01N 33/5032: {on intercellular interactions}
- G01N 33/507: {Pancreatic cells}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention is based, in part, on the discovery that a polypeptide, referred to herein as Betacam, is selectively expressed on the surface of pancreatic islet cells. Thus, in one aspect, the invention is directed to compositions comprising Betacam or that can be used to detect Betacam. In another aspect, the invention provides methods of detecting (e.g., non-invasively) pancreatic beta cells from a mammalian cell source. Another aspect of the invention is directed to cellular purification of pancreatic beta cells from a heterogeneous cell source of multiple kinds. In another aspect, the invention provides methods of identifying agents that modulate activity of Betacam. In yet another aspect, the invention provides for improved treatment and diagnosis of diabetes.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

A method of detecting beta cells in a mixture of pancreatic cells comprising detecting the presence of a polypeptide on the surface of the cells, wherein the polypeptide comprises SEQ ID NO: 14, SEQ ID NO: 15, an amino acid sequence that has at least 50% identity to SEQ ID NO: 14 or an amino acid sequence that has at least 50% identity to SEQ ID NO: 15, and detection of expression of the polypeptide on the surface of the cells indicates that the cells are pancreatic beta cells.

### Claim 8 (depends on 7)

The method of claim 7 further comprising isolating the pancreatic beta cells from the mixture of cells.

### Claim 9 (depends on 8)

The method of claim 8 wherein the pancreatic beta cells are isolated from a biological sample.

### Claim 10 (depends on 7)

The method of claim 7 wherein the biological sample is pancreatic tissue.

### Claim 11 (depends on 10)

The method of claim 10 wherein the pancreatic tissue is obtained from a cadaver.

### Claim 12 (depends on 7)

The method of claim 7 wherein expression of the polypeptide is detected using an antibody that has binding affinity for the polypeptide.

### Claim 13

A method of detecting pancreatic beta cells in an individual in need thereof, comprising administering to the individual an agent that detects the presence of a polypeptide on the surface of the pancreatic beta cells, wherein the polypeptide comprises SEQ ID NO: 14, SEQ ID NO: 15, an amino acid sequence that has at least 50% identity to SEQ ID NO: 14 or an amino acid sequence that has at least 50% identity to SEQ ID NO: 15.

### Claim 14 (depends on 13)

The method of claim 13 wherein the individual is being screened for a risk of developing diabetes.

### Claim 15 (depends on 13)

The method of claim 13 wherein the individual has diabetes.

### Claim 16 (depends on 15)

The method of claim 15 wherein the diabetes is Type I diabetes or Type II diabetes.

### Claim 17 (depends on 13)

The method of claim 13 wherein the individual has had an islet cell transplantation.

### Claim 18

A method of isolating pancreatic beta cells from a mixture of pancreatic cells comprising:
a) contacting the mixture with a reagent that specifically binds to a polypeptide present on the surface of pancreatic beta cells, wherein the polypeptide comprises SEQ ID NO: 14, SEQ ID NO: 15, an amino acid sequence that has at least 50% identity to SEQ ID NO: 14 or an amino acid sequence that has at least 50% identity to SEQ ID NO: 15, thereby producing a combination;
b) maintaining the combination under conditions in which the reagent binds to the polypeptide present on the surface of the pancreatic beta cells, thereby producing a complex of pancreatic beta cells bound to the reagent; and
c) separating the complex from the combination, thereby isolating pancreatic beta cells from the mixture of pancreatic cells.

### Claim 19 (depends on 18)

The method of claim 18 further comprising d) separating the pancreatic beta cells from the reagent.

### Claim 20 (depends on 18)

The method of claim 18 wherein the mixture of pancreatic beta cells is pancreatic tissue.

### Claim 21 (depends on 20)

The method of claim 20 wherein the pancreatic tissue is obtained from a cadaver.

### Claim 22 (depends on 18)

The method of claim 18 wherein the reagent is an antibody that has binding affinity for the polypeptide.

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)
